SEARCH:   Advanced

Blood, 15 April 2008, Vol. 111, No. 8, pp. 3931-3940. Prepublished online as a Blood First Edition Paper on December 26, 2007; DOI 10.1182/blood-2007-08-107748. This Article Full Text Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2007-08-107748v1 111/8/3931    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tiedt, R. Articles by Skoda, R. C. Search for Related Content PubMed PubMed Citation Articles by Tiedt, R. Articles by Skoda, R. C. Related Collections Neoplasia Plenary Papers Oncogenes and Tumor Suppressors Signal Transduction Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PLENARY PAPER Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice Ralph Tiedt1, Hui Hao-Shen1, Marta A. Sobas1,2, Renate Looser1, Stephan Dirnhofer3, Jürg Schwaller4, and Radek C. Skoda1 1 Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland; 2 Servicio de Hematologia y Hemoterapia, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; 3 Institute of Pathology, University Hospital Basel, Basel, Switzerland; and 4 Department of Research, Childhood Leukemia, University Hospital Basel, Basel, Switzerland An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis) can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites. Crossing mice of one transgenic line (FF1) with transgenic mice expressing Cre-recombinase under the control of the hematopoiesis specific Vav promoter led to expression of JAK2-V617F that was lower than the endogenous wild-type Jak2. These mice developed a phenotype resembling ET with strongly elevated platelet counts and moderate neutrophilia. Induction of the JAK2-V617F transgene with the interferon-inducible MxCre resulted in expression of JAK2-V617F approximately equal to wild-type Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis, and neutrophilia. Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis. These data are consistent with the hypothesis that the ratio of mutant to wild-type JAK2 is critical for the phenotypic manifestation. A similar correlation was also found in patients with MPD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: JAK2V617F: you can't have too much Ross L. Levine Blood 2008 111: 3913. [Full Text] [PDF] This article has been cited by other articles: S. Y. Cheranov, D. Wang, V. Kundumani-Sridharan, M. Karpurapu, Q. Zhang, K. R. Chava, and G. N. Rao The 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires Janus kinase 2-signal transducer and activator of transcription-5B-dependent expression of interleukin-8 Blood, June 4, 2009; 113(23): 6023 - 6033. [Abstract] [Full Text] [PDF] S. Gery, Q. Cao, S. Gueller, H. Xing, A. Tefferi, and H. P. Koeffler Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F J. Leukoc. Biol., June 1, 2009; 85(6): 957 - 965. [Abstract] [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] K. Hussein, O. Bock, K. Theophile, J. Schlue, M. Ballmaier, N. Kroger, G. Gohring, G. Busche, and H. Kreipe Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation Blood, February 5, 2009; 113(6): 1391 - 1392. [Full Text] [PDF] V. Senyuk, C. R. Rinaldi, D. Li, F. Cattaneo, A. Stojanovic, F. Pane, X. Du, N. Mahmud, J. Dickstein, and G. Nucifora Consistent Up-regulation of Stat3 Independently of Jak2 Mutations in a New Murine Model of Essential Thrombocythemia Cancer Res., January 1, 2009; 69(1): 262 - 271. [Abstract] [Full Text] [PDF] F. Passamonti and E. Rumi Clinical relevance of JAK2 (V617F) mutant allele burden Haematologica, January 1, 2009; 94(1): 7 - 10. [Full Text] [PDF] I. Plo, M. Nakatake, L. Malivert, J.-P. de Villartay, S. Giraudier, J.-L. Villeval, L. Wiesmuller, and W. Vainchenker JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders Blood, August 15, 2008; 112(4): 1402 - 1412. [Abstract] [Full Text] [PDF] A. M. Vannucchi and P. Guglielmelli Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations Haematologica, July 1, 2008; 93(7): 972 - 976. [Full Text] [PDF] S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice Blood, May 15, 2008; 111(10): 5109 - 5117. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020